2026.09.04 北海道大学 プレスリリース ポイント難治性の悪性リンパ腫「末梢性T細胞リンパ腫(PTCL)」の薬剤感受性メカニズムを解明。特定遺伝子の欠失により...

ISLAMABAD: The telecom sector regulator has directed all three telcos to implement a uniform policy on SIM expiry and recharge amounts, after finding that two telcos were not complying with the prescribed terms and conditions. A senior Pakistan Telecommunication Authority (PTA) official said consumers had lodged complaints against Zong and Telenor Pakistan, which has now been acquired by PTCL. The complainants had demanded that prepaid balance should remain valid for the entire active life of the SIM. “The complaints were that these two companies demanded that consumers maintain a certain amount of balance even during the active period of the SIMs, failing which the SIMs were eventually cancelled. The other issue was that they did not carry over the balance amount after the next recharge,” the official added. Zong and the merged company, Ufone/Telenor, did not respond to the query; however, a Jazz official said the active base of a SIM is 90 days, with 180 days as a quarantine period. > Orders companies to implement 180-day minimum balance validity policy “After that, the recycling of the SIM is allowed — that means the ownership of the SIM can be changed,” the official added. The official added that Jazz has a recycling policy under which any SIM that remains dormant for up to 720 days is recycled. “But after this period, a dormant SIM is allowed to be totally recycled, and the previous owner can no longer claim any rights over the recycled SIM,” the official added. The determination issued by the PTA directed all telcos to implement a minimum validity period of 180 days for any recharge/balance amount. The PTA has said any expired balance will automatically be reinstated and become usable upon a subsequent recharge during the active life of the SIM, as per the Telecom Consumers Protection Regulations. Telecom companies will not engage in any unfair commercial practices when implementing this decision, which will take effect on Oct 1. The PTA had received multiple complaints from subscribers regarding the forfeiture of unused prepaid balances upon expiry of validity periods. The complainants had said that such deduction and non-adjustment of the balance to subsequent recharges required intervention by the regulator. The complaint lodged with the PTA was that the non-adjustment of the remaining balance significantly impacts the average subscriber financially, particularly low-income subscribers. The PTA has noted that around 97 per cent of subscribers in Pakistan, Azad Jammu and Kashmir, and Gilgit-Baltistan are prepaid users. _Published in Dawn, August 30th, 2026_

Prof Marek Trněný speaks to ecancer about the phase 2 CHEPA study that evaluated the addition of etoposide to brentuximab vedotin plus CHP (CHEP) in prev

Background : T-cell acute lymphoblastic leukemia (T-ALL) and peripheral T-cell lymphoma (PTCL) are aggressive hematological malignancies requiring novel therapeutic strategies. The majority of T-ALL a...

Intelligence report on 182.186.58.61: DMARC spoofing activity, network ownership, geolocation data. Track email security threats and investigate suspicious IPs. Free threat intelligence.

2026.08.06 北海道大学 プレスリリース ポイント難治性の悪性リンパ腫「末梢性 T 細胞リンパ腫(PTCL)」の新規治療戦略を開発。PTCL に対して BV と相乗効果を...

Intelligence report on 116.71.176.98: DMARC spoofing activity, network ownership, geolocation data. Track email security threats and investigate suspicious IPs. Free threat intelligence.

ISLAMABAD – What began with PTCL’s acquisition of Telenor Pakistan could now lead to one of Pakistan’s biggest fintech deals.…

🎗️ 犬猫 腫瘍ニュース — 2026.07.29 犬猫の腫瘍・がん関連ニュース＆論文 計7件 🎗️ 腫瘍・がん関連ニュース — 2026.07.29 本日 7件 1. 🎗️ 医療・血液がん治療 犬の「末梢性T細胞リンパ腫」に標的放射性医薬品──⁹⁰Y-NM600がん細胞をピンポイント照射する新戦略 📅 2026 米ウィスコンシン大学は、同大カーボンがんセンターと連携し、犬の「末梢性T細胞リンパ腫（PTCL）」に対する新しい治療法の臨床試験を進めている。用いるのは⁹⁰Y-NM600と呼ばれる「標的放射性医薬品」で、がん細胞に集まりやすい性質を持つ分子に放射性同位体（イットリウム90）を結合させ、体の中からがん細胞をピンポイントで照射する仕組みだ。外部から当てる放射線治療と違い、全身に散らばったがん細胞にも届く可能性がある。 末梢性T細胞リンパ腫は、犬のリンパ腫の中でも標準的な化学療法が効きにくく予後が厳しいタイプとして知られる。体内から狙い撃ちする放射性医薬品は、正常組織へのダメージを抑えつつ、これまで手を出しにくかった微小な転移巣にもアプローチできると期待されている。この治療はヒトの難治性リンパ腫の研究とも共通点が多く、まさに「比較腫瘍学」の一例だ。愛犬がリンパ腫と診断された場合、標準治療に加えて臨床試験という選択肢があることも、主治医に相談してみる価値がある。 🔗 🏷️ 医療・疾病・予防 2. 🎗️ 研究・個別化治療 【日本】犬の前立腺がんは「BRAF変異」が多い──ヒトのがんで使う分子標的薬の応用へ、東大が治療開発 📅 2026 東京大学の獣医外科学研究室は、犬の前立腺がんに対する「BRAF/MEK阻害療法」の開発を進めている。犬の尿路上皮がん（膀胱がん）や前立腺がんの多くでは、細胞増殖のスイッチを担うBRAF遺伝子の特定部位（コドン595）に高い確率で点突然変異（V595E）が見つかっており、この変異は正常な細胞には見られない。つまり、この変異こそが"がんの弱点"になりうるという発想だ。 BRAF変異はヒトの悪性黒色腫（メラノーマ）などでも重要な治療標的で、すでにBRAF阻害薬やMEK阻害薬といった分子標的薬が使われている。これらの薬を犬の前立腺がんに応用できれば、副作用の大きい従来の抗がん剤に頼らない、より的を絞った治療につながる可能性がある。犬の前立腺がんは進行が速く治療が難しいがんの一つだけに、日本発の個別化医療の研究が待たれる。愛犬に頻尿や排尿困難などの症状があれば、早めに受診してほしい。 🔗 🏷️ 研究・科学 3. 🎗️ 医療・新治療 犬の甲状腺腫瘍を「切らずに壊す」ヒストトリプシー──焦点式超音波が免疫まで呼び覚ます 📅 2026.05 米バージニア工科大学の研究チームは、犬の甲状腺腫瘍を切開も放射線も使わずに治療する「ヒストトリプシー」の臨床研究を進めている。ヒストトリプシーは、焦点を絞った超音波の力で組織内に微小な泡（キャビテーション）を発生させ、その物理的な力だけで腫瘍を精密に破壊する非侵襲・非加熱・非電離の新技術だ。メスを入れず、熱で焼くのでもなく、狙った場所の細胞を機械的に砕く点が特徴である。 さらに近年の研究では、ヒストトリプシーで壊されたがん細胞のかけらが免疫系を刺激し、体自身のがんに対する防御反応を呼び覚ます可能性が注目されている。同大は2020年からNIH（米国立衛生研究所）や焦点式超音波財団などの支援を受けて犬の臨床試験を続けており、甲状腺のほか肝臓・骨・脳の腫瘍にも応用研究を広げている。体への負担が小さい治療は、高齢の犬や手術リスクの高い症例にとって大きな希望になりうる。 🔗 🏷️ 医療・疾病・予防 4. 🐱 猫の腫瘍・比較腫瘍学 猫の扁平上皮癌に「STAT3阻害薬」──35%で病勢を制御、ヒトの頭頸部がんにも道 📅 2026 米カリフォルニア大学サンフランシスコ校（UCSF）とデービス校（UC Davis）の研究チームは、飼い猫を対象にした新しい抗がん薬の初の臨床試験を実施し、その結果を学術誌Cancer Cellに発表した。対象は、猫の口や皮膚にできる悪性度の高い「扁平上皮癌（へんぺいじょうひがん）」。がん細胞の増殖に関わるタンパク質「STAT3」を阻害する新薬を投与したところ、治療を受けた猫の35%で病気の進行が抑えられ、しかも副作用はごく軽かった。 この研究を率いたUCSFのジェニファー・グランディス博士らは、猫の扁平上皮癌がヒトの「頭頸部扁平上皮癌（HNSCC）」とよく似ていることに着目した。飼い猫での成果は、そのままヒトの難治がんの新薬開発にも道を開く「比較腫瘍学」の好例だ。猫の口のがんは進行が速く、これまで有効な内科治療が乏しかっただけに、副作用の少ない新しい選択肢は朗報といえる。愛猫の口臭・よだれ・食べにくさなどが続く場合は、早めに口の中を診てもらってほしい。 🔗 …

Journal of Clinical Oncology (JCO) Podcast · Episode

Intelligence report on 59.103.43.7: DMARC spoofing activity, network ownership, geolocation data. Track email security threats and investigate suspicious IPs. Free threat intelligence.

Intelligence report on 182.186.78.242: DMARC spoofing activity, network ownership, geolocation data. Track email security threats and investigate suspicious IPs. Free threat intelligence.

YouTube video by HOPE-PTCL

ISLAMABAD: The new management of Ufone and Telenor Pakistan has decided to rebrand the merged telecom company and has filed an application with the Pakistan Telecommunication Authority (PTA) in this regard, it emerged on Monday. Earlier this month, the Telenor Pakistan was formally amalgamated into Pak Telecom Mobile Limited (PTML) — the legal name for Ufone — after final approval by the Islamabad High Court (IHC). Sources in Pakistan Telecommunication Company Ltd (PTCL) confirmed that the name of the new merged company would be “e&”, signifying that the merged telecom entity is under UAE-based state-owned company Etisalat. PTCL had already written a letter to the Pakistan Telecommunication Authority (PTA) seeking a new brand name for the merged company, while the telecom regulator responded that a notification from the Securities and Exchange Commission of Pakistan (SECP) was required regarding the names of the directors of the merged entity. Similarly, the PTA had also responded to a letter written by PTML regarding the registration of the new brand, directing the company that an SECP notification was essential. “Ufone is a brand of Pak Telecom Mobile Limited (PTML), and as Telenor Pakistan has been amalgamated into it, there could be a change in PTML directors,” said an official of the Ministry of Information Technology and Telecommunications, adding that a notification regarding any change or no change in the board had to be issued by the SECP. The letter available with _Dawn_ shows that the PTA directed PTML that the launch and advertising of any new brand could not be carried out without an SECP notification. PTCL has been bifurcated as per the decision of the Competition Commission of Pakistan (CCP) regarding the merger of Telenor Pakistan into PTCL. As per the bifurcation, PTCL and its other subsidiaries have been separated from the mobile telecommunications business. The government holds around a 62pc stake in PTCL, while 26pc of shares and management control are held by Abu Dhabi–owned telecom giant Etisalat — which has recently rebranded as “e&” (Etisalat and). The remaining 12pc shares are held by private investors through the Pakistan Stock Exchange (PSX). However, a senior official of the IT Ministry told _Dawn_ that giving the brand name “e&” to the merged company — Ufone and Telenor — could face serious legal objections, as it would still be a subsidiary of PTML. “PTML is a subsidiary of PTCL — a state-owned enterprise — and PTML is not under Etisalat,” the official said, adding that, legally, this could amount to a copyright violation of an international brand, or the merged telecom company would have to pay a royalty fee to Etisalat. He further said that PTCL was already paying profits to the UAE-based company despite the fact that the PTCL group had been making losses for a long time.